Pramipexole Ameliorates Neurologic and Psychiatric Symptoms in a Westphal Variant of Huntington's Disease
- 1 January 2002
- journal article
- case report
- Published by Ovid Technologies (Wolters Kluwer Health) in Clinical Neuropharmacology
- Vol. 25 (1), 58-60
- https://doi.org/10.1097/00002826-200201000-00011
Abstract
Levodopa is recommended as a therapeutic approach for patients with the hypokinetic-rigid, Westphal variant of Huntington's disease, but no guidelines are available for the case of nonrespondence to levodopa. In this study, however, we report a 34-year-old woman with this rare variant who showed a clear-cut improvement in motor function and depressive symptoms after treatment with pramipexole, a new dopamine agonist.Keywords
This publication has 9 references indexed in Scilit:
- A Five-Year Study of the Incidence of Dyskinesia in Patients with Early Parkinson's Disease Who Were Treated with Ropinirole or LevodopaNew England Journal of Medicine, 2000
- Late onset levodopa responsive Huntington's disease with minimal chorea masquerading as Parkinson plus syndromeJournal of Neurology, Neurosurgery & Psychiatry, 2000
- Treatment of Parkinson's disease should begin with a dopamine agonistMovement Disorders, 1999
- Pramipexole — a new dopamine agonist for the treatment of Parkinson's diseaseJournal of the Neurological Sciences, 1999
- Levodopa responsive parkinsonism in an adult with Huntington's diseaseJournal of Neurology, Neurosurgery & Psychiatry, 1998
- The mesolimbic dopamine system as a target for rapid antidepressant actionInternational Clinical Psychopharmacology, 1997
- Neurochemical substrates of rigidity and chorea in Huntington's diseaseBrain, 1993
- Preferential loss of striato‐external pallidal projection neurons in presymptomatic Huntington's diseaseAnnals of Neurology, 1992
- Striatal and nigral neuron subpopulations in rigid Huntington's disease: Implications for the functional anatomy of chorea and rigidity‐akinesiaAnnals of Neurology, 1990